PTIE - Pain Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
4.20
-0.05 (-1.18%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.25
Open4.40
Bid4.07 x 1500
Ask5.60 x 800
Day's Range4.14 - 4.75
52 Week Range3.10 - 9.31
Volume258,800
Avg. Volume391,462
Market Cap27.701M
Beta1.57
PE Ratio (TTM)N/A
EPS (TTM)-1.87
Earnings DateFeb 15, 2018 - Feb 19, 2018
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2012-12-13
1y Target Est23.75
Trade prices are not sourced from all markets
  • GlobeNewswire22 hours ago

    Pain Therapeutics Announces New Publication on Alzheimer’s Disease

    AUSTIN, Texas, Dec. 14, 2017-- Pain Therapeutics, Inc., a biopharmaceutical company, today announced a new publication for PTI-125, a clinical-stage drug candidate with a novel mechanism of action for ...

  • Should You Be Concerned About Pain Therapeutics Inc’s (PTIE) Shareholders?
    Simply Wall St.last month

    Should You Be Concerned About Pain Therapeutics Inc’s (PTIE) Shareholders?

    In this article, I will take a quick look at Pain Therapeutics Inc’s (NASDAQ:PTIE) recent ownership structure – an unconventional investing subject, but an important one. A company’s ownership structureRead More...

  • Associated Presslast month

    Pain Therapeutics reports 3Q loss

    The Austin, Texas-based company said it had a loss of 40 cents per share. The company's shares closed at $3.53. A year ago, they were trading at $3.93. _____ This story was generated by Automated Insights ...

  • GlobeNewswirelast month

    Pain Therapeutics Reports Third Quarter 2017 Financial Results

    AUSTIN, Texas, Nov. 01, 2017-- Pain Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2017. Net loss for the third quarter of 2017 was $2.6 million, or $0.40 ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Stocks to Watch: Pain Therapeutics and Ionis Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 25, 2017 / Pain Therapeutics saw its shares explode in Tuesday trading after positive results were revealed from the Phase 1 study of its PTI-125 drug to treat Alzheimer's. ...

  • Pain Therapeutics, Inc. (PTIE) Shares Fire Up To The Roof; Here’s Why
    SmarterAnalyst2 months ago

    Pain Therapeutics, Inc. (PTIE) Shares Fire Up To The Roof; Here’s Why

    Pain Therapeutics, Inc. (NASDAQ:PTIE) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 60% upturn. Why such a bullish parade? A Phase 1 clinical trial of PTIE’s new investigational drug, PTI-125, showed that it was safe and well-tolerated in healthy volunteers, paving the way for a Phase 2 trial in adults with Alzheimer’s Disease. In September, the company announced it has been awarded an approximately $1.8 million research grant from the National Institutes of Health (NIH).  This grant will support innovative technology developed by the Company to diagnose Alzheimer's disease with a simple blood test.

  • GlobeNewswire2 months ago

    Pain Therapeutics Announces Successful Phase I Clinical Study for PTI-125

    AUSTIN, Texas, Oct. 24, 2017-- Pain Therapeutics, Inc. announced today the completion of a Phase I clinical study for PTI-125, a new experimental drug therapy to treat Alzheimer’ s Disease. This study ...

  • Healthcare Industry Trends And Its Impact On Pain Therapeutics Inc (PTIE)
    Simply Wall St.2 months ago

    Healthcare Industry Trends And Its Impact On Pain Therapeutics Inc (PTIE)

    Pain Therapeutics Inc (NASDAQ:PTIE), a USD$26.78M small-cap, operates in the healthcare industry, which continues to endure a more demanding healthcare agenda, and the global need for innovative, cost-effective medicines continuesRead More...

  • How Should You Think About Pain Therapeutics Inc’s (PTIE) Risks?
    Simply Wall St.2 months ago

    How Should You Think About Pain Therapeutics Inc’s (PTIE) Risks?

    If you are a shareholder in Pain Therapeutics Inc’s (NASDAQ:PTIE), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • GlobeNewswire3 months ago

    NIH Awards $1.8 Million Research Grant to Pain Therapeutics in Support of a Blood-based Diagnostic for Alzheimer’s Disease

    AUSTIN, Texas, Sept. 18, 2017-- Pain Therapeutics, Inc., a biopharmaceutical company, announced today it has been awarded an approximately $1.8 million research grant from the National Institutes of Health. ...

  • GlobeNewswire3 months ago

    National Institute on Drug Abuse Awards Pain Therapeutics $2.2 Million Grant

    AUSTIN, Texas, Sept. 18, 2017-- Pain Therapeutics, Inc., a biopharmaceutical company, today announced that it has been awarded a research and development grant from the National Institute on Drug Abuse. ...

  • Associated Press4 months ago

    Pain Therapeutics reports 2Q loss

    On a per-share basis, the Austin, Texas-based company said it had a loss of 64 cents. The company's shares closed at $3.38. A year ago, they were trading at $18.23. _____ This story was generated by Automated ...

  • Associated Press8 months ago

    Pain Therapeutics reports 1Q loss

    The Austin, Texas-based company said it had a loss of 6 cents per share. In the final minutes of trading on Tuesday, the company's shares hit 80 cents. A year ago, they were trading at $2.55. _____ This ...

  • Investopedia9 months ago

    Pain Therapeutics’ Remoxy ER Secures FDA Regulatory Guidance (PTIE,EGLT)

    Following the positive update, Pain Therapeutics stock spiked by around 61% to hit $1.10 per share during after hours trading on Monday.

  • Here’s What The Latest Pain Therapeutics, Inc. (PTIE) Update Means
    Insider Monkey10 months ago

    Here’s What The Latest Pain Therapeutics, Inc. (PTIE) Update Means

    Pain Therapeutics, Inc. (NASDAQ:PTIE) put out a fourth-quarter business update, and alongside it, gave us some insight into the possible future of the company’s long suffering abuse deterrent asset, Remoxy. This is one that we have covered in the past on a number of occasions here Market Exclusive, yet one that remains on an as-yet […]

  • Associated Press10 months ago

    Pain Therapeutics reports 4Q loss

    The Austin, Texas-based company said it had a loss of 6 cents per share. For the year, the company reported a loss of $14.9 million, or 33 cents per share, swinging to a loss in the period. The company's ...

  • Pain Therapeutics, Inc. (PTIE): How Does It Compare Against Its Peers?
    Insider Monkeylast year

    Pain Therapeutics, Inc. (PTIE): How Does It Compare Against Its Peers?

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]